Lexicon Pharma (LXRX) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.42 -4.05%
EPS Growth %: -50.0%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -50.0%
Financial Fact:
Collaborative research: 27.69M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $234 thousand, versus $9.16 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- enVVeno Medical (NVNO) Misses Q3 EPS by 302c
- Morgan Stanley Upgrades CaixaBank SA (CABK:SM) (CAIXY) to Overweight, Top Pick
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
